Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: My Covid symptoms (mainly severe congestion, headache, fatigue, and sore throat) all re-emerged within four days of discontinuing Paxlovid.; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (My Covid symptoms (mainly severe congestion, headache, fatigue, and sore throat) all re-emerged within four days of discontinuing Paxlovid.) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Johnson and Johnson (Dose Number: 1. Batch/Lot No: Unknown. Location of injection: Arm Left.) on 23-Mar-2021. Past adverse reactions to the above products included No adverse event with Johnson and Johnson. Concomitant products included ARTEMISIA ABSINTHIUM HERB (WORMWOOD) from 10-May-2022 to 14-May-2022 for an unknown indication.    On 15-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (My Covid symptoms (mainly severe congestion, headache, fatigue, and sore throat) all re-emerged within four days of discontinuing Paxlovid.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 10-May-2022 to 14-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (My Covid symptoms (mainly severe congestion, headache, fatigue, and sore throat) all re-emerged within four days of discontinuing Paxlovid.) was resolving.            Patient received Moderna as a booster dose (after receiving dose 1 of Johnson and Johnson vaccine).  Concomitant products included Vitamin B, D, and Chinese herbal supplement from 01-Jan-2022 to 09-May-2022 for an unknown indication.  The patient COVID symptoms (mainly severe congestion, headache, fatigue, and sore throat) all re-emerged within four days (18-May-2022) of discontinuing Paxlovid  Device date was reported as 24-May-2022.  Company comment: This is a spontaneous case concerning a 27-year-old, female patient with no reported medical history and with vaccine history of receiving first dose of Johnson and Johnson, who experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 6 to 7 months after the second dose of mRNA-1273 vaccine administration in Covid-19 vaccination in series. The event was described as, patient experienced Covid-19 and took Nirmatrelvir + Ritonavir (Paxlovid). Patient's symptoms of severe congestion, headache, fatigue and sore throat re-emerged within 4 days of discontinuing Paxlovid. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report; Sender's Comments: This is a spontaneous case concerning a 27-year-old, female patient with no reported medical history and with vaccine history of receiving first dose of Johnson and Johnson, who experienced the unexpected non-serious AESI event of Covid-19. The event occurred approximately 6 to 7 months after the second dose of mRNA-1273 vaccine administration in Covid-19 vaccination in series. The event was described as, patient experienced Covid-19 and took Nirmatrelvir + Ritonavir (Paxlovid). Patient's symptoms of severe congestion, headache, fatigue and sore throat re-emerged within 4 days of discontinuing Paxlovid. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.